Experimental drug TAK-243 targets tough blood cancers in early trial
NCT ID NCT03816319
First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-243
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat blood cancers that have stopped responding to standard therapy.
- What could go wrong
- This is a very early (Phase 1) trial that is currently suspended, so results are uncertain. The drug may not work or may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
University Health Network-Princess Margaret Hospital
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Email: •••••@•••••
-
VCU Massey Comprehensive Cancer Center
RECRUITINGRichmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lab-Grown stem cells could speed immune recovery in blood cancer transplants
- Could a targeted drug keep AML in check?
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications